| 证券代码 | KERX.O |
| 证券名称 | 克律克斯生物制药 |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2000-07-28 |
| 首发价格(元) | 10 USD |
| 首发数量(股) | 4600000 |
| 首发募资额(元) | 46,000,000.00 USD |
| 首发主承销商 | CIBC World Markets Corp |
| 货币单位 | USD |
| 公司名称 | Keryx Biopharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | One Marina Park Drive, 12th Floor, Boston, Massachusetts, USA |
| 成立日期 | 1998-10 |
| 董事会主席 | Michael Rogers |
| 公司属地 | United States 美国 |
| 公司网址 | www.keryx.com |
| 电话 | +1 (617) 466-3500 |
| 传真 | +1 (617) 466-3501 |
| 公司简介 | Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia (ferric citrate), an iron-based phosphate binder, in the U.S. Ferric citrate is marketed as Riona by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. |